Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older-Reference-Cited by-同舟云学术

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

Published:2023-11-08 Issue:1 Volume:22 Page:1079-1090
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Chen Yingping¹,Zhang Xinpei²,Gong Lihui³,Liang Zhenzhen¹,Hu Xiaosong¹,Xing Bo¹,Liao Yuting⁴,Yuan Lingfeng³,Chen Gang³,Lv Huakun¹

Affiliation:

1. Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China

2. Office, Shangyu District Center for Disease Control and Prevention, Shaoxing, China

3. Clinical Department, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Hefei, China

4. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China

Funder

Key Program of Health Commission of Zhejiang Province/Science Foundation of National Health Commission

Medical and Health Science and Technology Program of Zhejiang Province

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2023.2274491

Reference31 articles.

1. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

2. Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

3. Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine

4. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

5. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3